Background
==========

Cardiovascular disease (CVD) is the world's most important cause of death, driven by the high rates of coronary heart disease and stroke in five out of the six World Health Organization regions ([@b67]). Since CVD also drives high healthcare costs in those surviving events such as stroke and heart failure, better strategies to facilitate the prevention and treatment of cardiovascular disease have become priorities for most healthcare systems.

Cardiovascular risk factors
---------------------------

The major modifiable risk factors for cardiovascular disease are well documented, with the principal three being: abnormal plasma lipid levels (high levels of low-density lipoprotein cholesterol \[LDL-C\] and triglycerides, and low levels of high-density lipoprotein cholesterol \[HDL-C\]) ([@b3]; [@b61]); hypertension ([@b39]); and smoking ([@b41]; [@b23]). Several large epidemiological surveys have shown that 80%--90% of patients with coronary heart disease have at least one of these three risk factors ([@b46]), and that each risk factor has a continuous, severity-dependent impact on risk for coronary heart disease ([@b43]; [@b42]; [@b57]). Additional cardiovascular risk factors include age (≥55 years), male gender, presence of other vascular disease (history of stroke or peripheral arterial disease), diabetes mellitus ([@b26]), proteinuria, left ventricular hypertrophy, and family history of premature coronary heart disease.

Cardiovascular risk factors rarely occur in isolation and many subjects present with a combination of conditions that contribute to their total risk of cardiovascular disease ([@b37]; [@b32]). According to an analysis based on Framingham data, 78% of hypertensive men and 82% of hypertensive women have at least one other cardiovascular risk factor ([@b35]). The principal European CVD risk study, the WHO MONItoring of trends and determinants in CArdiovascular disease (MONICA) project, indicated that approximately 35% of Western Europeans have both conditions ([@b58]). Similar studies of CVD risk factors in France showed that 84% of hypertensive men and 77% of hypertensive women have at least one other cardiovascular risk factor ([@b4]), and that 20% of adults in the United Kingdom (UK) have concomitant hypertension and dyslipidemia (representing 9.2 million people) ([@b63]). These findings are of major clinical significance, since even borderline elevations in both blood pressure (BP) and serum cholesterol can dramatically increase the prevalence of cardiovascular disease and the risk of coronary heart disease.

Prevention guidelines from the US ([@b42]; [@b12]), Canada ([@b36]), and Europe ([@b25]; [@b63]) highlight the need for an overall approach towards assessment of a patient's risk of morbidity and mortality from cardiovascular disease. These guidelines recommend assessment of total cardiovascular risk and encourage individually tailored therapy to address all risk factors.

Managing cardiovascular risk and current practice
-------------------------------------------------

Encouraging lifestyle modifications should be the cornerstone of all treatment programs ([@b42]; [@b63]); however lifestyle modifications are not always successful or sufficient on their own ([@b18]). Large clinical outcome trials have shown that cardiovascular morbidity and mortality can be reduced significantly by the use of antihypertensive agents ([@b2]; [@b59]; [@b34]) and lipid-lowering drugs, particularly statins ([@b28]; [@b55]) in both secondary ([@b53]) and primary prevention ([@b56]).

Further evidence has accumulated to guide how intensively patients at risk should be treated. Targets for BP are based on meta-analyses from the major trials ([@b9]; [@b60]) and especially the results of large outcomes trials ([@b27]). Targets for LDL-C were set initially on the basis of older landmark statin studies ([@b53]; [@b55]); however there have been calls to further reduce these goals ([@b24]) on the basis of more recent trials, which indicate that risk of cardiovascular disease can be further lowered by treating to more aggressive targets ([@b10]; [@b45]). Furthermore, mortality improvements have been observed in patients with multiple risk factors, but only normal to mildly elevated cholesterol at baseline (mean total cholesterol ≤6.5 mmol/L in ASCOT) ([@b55]). For lipid lowering, it is known from MRFIT that every 0.5 mmol/L increase in total cholesterol corresponds to an increase in CHD mortality risk of 12% and an increase in mortality risk of 17% when adjusted for regression dilution bias. Furthermore, the major lipid reduction trials have shown that every 1 mmol/L reduction in TC was associated with a 23% reduction in CHD and 21% reduction in total vascular risk ([@b6]). There is also strong evidence from intervention trials that benefit of this magnitude is achieved whichever method is used to reduce cholesterol levels.

Guidelines for management of cardiovascular risk factors rely on physicians and patients recognizing the need to reduce cardiovascular risk and accepting the huge evidence-base supporting the recommended interventions. However, the observed suboptimal treatment patterns and failure to achieve guideline-recommended treatment goals ([Figure 1](#fig1){ref-type="fig"}) are compounded by patient non-concordance with prescribed therapies -- up to 50% of patients choose to stop their medication of their own volition for a variety of reasons ([@b30]), and often within a few months of starting treatment. Clearly, adherence to treatment will influence whether benefits are translated into reductions in morbidity and mortality ([@b56]; [@b20]). Factors reported to influence adherence include patient education, cost, patients' attitudes towards treatment, differences in dosing regimens, history of cardiovascular disease, numbers of concomitant medications and side effects ([@b54]; [@b11]). There are reasons in addition to non-adherence, which may help to explain why treated patients do not attain target levels, for example, lack of response to a specific therapy.
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Physician performance in delivering guideline recommendations for CVD risk
--------------------------------------------------------------------------

Despite the widely acknowledged severe burden of cardiovascular disease, previous studies conducted in a variety of locations and settings have demonstrated that many patients at risk remain unidentified and or untreated. One survey conducted in Europe and Canada has indicated that up to 60% of treatment-eligible patients are not receiving treatment for their hypertension, ranging from 38% in Canada, to 59% in Germany ([@b66]). A similar pattern has been recorded for patients with coronary heart disease and elevated lipid levels in Europe (EUROASPIRE I and II Group).

The way physicians increment therapy also contributes to under-treatment: typically, physicians treat patients with additional cardiovascular risk factors by managing each risk factor separately, often sequentially rather than in parallel ([@b49]; [@b51]). This approach adds to pill burden and requires multiple physician visits to achieve appropriate drug titration for each risk factor. Even among those patients receiving adequate treatment for both conditions, few patients are at goal. This treatment gap could widen as target levels are reduced ([@b24]). There is also suboptimal management and little improvement over time of other cardiovascular disease risk factors, such as smoking and obesity ([@b51]; [@b1]).

Patient factors that influence patient concordance with therapy
---------------------------------------------------------------

In a retrospective cohort study of patients in a US managed-care plan, it was found that adherence to concomitant antihypertensive and lipid-lowering therapy was poor, with only one in three patients adherent to both medications at 6-months ([@b66]). Pill count is an important issue, since patients are less likely to refill their antihypertensive and lipid-lowering prescriptions as their total number of prescriptions increases ([@b66]). Synchronization of antihypertensive and lipid-lowering therapy initiation (ie, initiating both therapies simultaneously) also improves adherence in comparison with patients starting one therapy more than 30-days prior to the other ([@b1]), and adherence decreases as the time between initiation of antihypertensive and lipid-lowering therapies is prolonged ([@b66]). Increased cost of multiple prescriptions has been shown to have a large impact on adherence. For example, 25% of senior (\>65 years) Medicare beneficiaries in a 2003 survey reported forgoing prescription medications in the past year because of cost ([@b52]).

Physicians may therefore be able to significantly improve medication adherence by initiating antihypertensive and lipid-lowering therapy concomitantly and by reducing pill burden and costs to the patient -- goals that may be aided by single-pill therapy combining an antihypertensive with a lipid lowering agent. Patient adherence to medication has been shown to be significantly greater with a single-pill regimen compared with a two-pill regimen for antihypertensive therapy alone ([@b34]), and also when antihypertensive and lipid-lowering therapies are initiated together versus sequentially ([@b66]; [@b15]).

Rationale for amlodipine besylate/atorvastatin calcium combination
==================================================================

With evidence showing that drug combinations improve patient compliance and persistence with therapy, this provides the rationale for the amlodipine besylate/atorvastatin calcium combination -- a single-pill medication that treats both hypertension and dyslipidemia.

Amlodipine component
--------------------

Amlodipine besylate is approved for the treatment of hypertension and both vasospastic and chronic stable angina, alone or in combination with other agents. Amlodipine has been demonstrated to be well tolerated and effective at lowering BP in a wide variety of patients at risk of cardiovascular disease ([@b2]; [@b7]; [@b34]; [@b15]). It has been shown to reduce cardiovascular events in both hypertensive patients ([@b15]; [@b52]; [@b1]) and normotensive patients with coronary artery disease ([@b52]).

The primary action of calcium channel blockers is to inhibit calcium (Ca^2+^) entry through voltage-gated transmembrane L-type channels, thus decreasing intracellular Ca^2+^ concentration and inducing smooth muscle relaxation. Amlodipine has been tested extensively in clinical trials and has been used for the treatment of hypertension since 1990 in Europe and 1992 in the US.

Atorvastatin component
----------------------

Atorvastatin calcium is a synthetic lipid-lowering agent, available in dosage strengths of 10, 20, 40, or 80 mg. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate. This action occurs at an early and rate-limiting step in cholesterol biosynthesis and, consequently, is an important target for the development of cholesterol-lowering agents ([@b33]). Inhibition of HMG-CoA reductase leads to upregulation of LDL-receptors in the liver, mediated by activation of sterol regulatory element-binding proteins and enhanced clearance of LDL from the circulation. Because lipoproteins that infiltrate the vessel wall initiate the development of atherosclerotic lesions, and oxidized LDL particles may trigger or enhance atherogenicity, HMG-CoA reductase inhibitors (statins) have an important role in therapy to prevent atherosclerosis.

Atorvastatin, a second-generation statin, was introduced in 1996 and gives LDL-C reductions of 41%--61% in hypercholesterolemic patients. Individualization of drug dosage should be based on therapeutic response. Atorvastatin has been extensively tested in clinical trials and has shown impressive reductions in cardiovascular events ([@b24]). The efficacy of atorvastatin monotherapy also has been demonstrated in diverse patient types analyzed in major clinical endpoint trials ([@b5]; [@b10]; [@b13]).

In addition to the treatment of hypercholesterolemia, atorvastatin is indicated for reducing the risk of cardiovascular disease events in diabetic patients without clinically evident coronary heart disease, but with at least one additional cardiovascular risk factor. Furthermore, details of the CV benefits observed in hypertensive patients with 3 or more additional risk factors in ASCOT-LLA are included in the UK label, although an indication for the prevention of CV events in this group of patients is not mentioned specifically.

Amlodipine and atorvastatin have therefore been shown in major outcome studies to be safe and effective. There are no reported safety issues with the combined use of these two medications. Each is effective in the target population of the other, and neither component negatively impacts the efficacy of the other. In terms of pharmacokinetics, both agents have long half-lives, allowing once-daily administration. Both agents can be dosed at any time of the day. Neither drug has any interaction with foods, or affects the other drug's pharmacokinetic profile.

Simplifying drug regimens and reducing "pill burden" have been shown to enhance patient adherence. This could be particularly relevant for patients at high risk of cardiovascular disease who will often be prescribed complex drug regimens to appropriately manage their multiple cardiovascular risk factors. The logic of combining multiple risk interventions for this multifactorial disease has been widely debated following the concept of the "polypill" for cardiovascular disease prevention ([@b38]; [@b62]).

Clinical evidence for amlodipine/atorvastatin (Caduet) combination therapy
==========================================================================

Pre-registration studies of Caduet were extensive, using Atorvastatin and Amlodipine pills separately but concurrently. Co-administration of amlodipine and atorvastatin has been demonstrated to be safe and effective for lowering both BP and LDL-C in patients with concomitant hypertension and dyslipidemia ([@b8]; [@b16]; [@b40]). The half-lives of both agents facilitate once-daily dosing, and both can be administered at any time of day with or without food ([@b47]). Neither drug has any adverse effects on the other's efficacy or tolerability ([@b48], [@b50]; [@b29]). Bioequivalence has been demonstrated for both amlodipine and atorvastatin when fixed-dose combination tablets in strengths of 5/10 or 10/80 mg amlodipine/atorvastatin were compared with commercially available amlodipine and atorvastatin tablets coadministered in matching doses ([@b19]).

Following successful registration, amlodipine/atorvastatin (Caduet) tablets are available for oral administration in 11 dose-strength combinations for use in the US. In some countries of the European Union two dose strengths are available (5 mg amlodipine/10 mg atorvastatin, and 10 mg amlodipine/10 mg atorvastatin). Single-pill amlodipine/atorvastatin is indicated in Europe for the prevention of cardiovascular events in hypertensive patients, with three concomitant cardiovascular risk factors, normal to mildly elevated cholesterol levels, and without clinically evident coronary heart disease where combined use of amlodipine and low dose atorvastatin is appropriate.

Since registration, several clinical trials have been conducted to assess the efficacy and safety of the combination therapy.

GEMINI ([@b65])
---------------

GEMINI was the first Real World trial conducted to examine the use of amlodipine/atorvastatin (Caduet) single-pill therapy for the concomitant treatment of hypertension and dyslipidemia ([@b65]). This 14-week, open-label, non-comparative, multicenter trial based in the US demonstrated the broad utility of the combination treatment in getting 1220 patients with uncontrolled hypertension and concurrent dyslipidemia to achieve both BP and LDL-C goals, based on JNC VI and NCEP ATP guidelines ([Figure 2](#fig2){ref-type="fig"}). At study end, more than half of the patients had reached both their BP and LDL-C therapeutic targets. Over 65% of patients reached their respective Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure VI (JNC VI) goal at study end, and 82% attained their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) goal. [Figure 1](#fig1){ref-type="fig"} shows the percentages of patients reaching their BP, LDL-C or both therapeutic targets, based on baseline CVD risk category ([@b65]). Data were also presented regarding the performance of Caduet in patients who meet the IDF criteris for the metabolic syndrome (IDF).
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The open-label GEMINI study also demonstrated that the amlodipine/atorvastatin single pill has a safety profile in a real-world office setting consistent with its components, as previously documented in randomized, controlled clinical trials, including RESPOND and AVALON ([@b19]; [@b29]). In GEMINI, the most frequently reported adverse events (regardless of cause) were respiratory tract infections (11.9%), peripheral edema (8.8%), headache (5.4%) and myalgia (4.2%).These data demonstrated that co-administered amlodipine plus atorvastatin is well tolerated in patients with hypertension and additional risk factors, and that the adverse events observed are similar in nature, severity and frequency to those seen with amlodipine or atorvastatin administered alone.

The JEWEL Program ([@b29])
--------------------------

This program consisted of two 16-week, international, open-label, multicenter, titration-to-goal studies (JEWEL I and II) in 2219 patients with hypertension and dyslipidemia. The two studies differed based on country of enrollment (I with 1135 patients was based in the UK and Canada ([@b44]), and II with 1034 patients was based in 8 other major European countries) and primary endpoints in terms of treatment targets -- these were determined by what the prevailing targets were by country (Canada, UK \[audit targets\], and European Society of Cardiology \[[@b14]\] guidelines) as seen in [Figure 4](#fig4){ref-type="fig"}. Patients were initiated at a dose of amlodipine besylate 5 mg/atorvastatin calcium 10 mg, and the dose was uptitrated as necessary.
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Different combinations of doses of amlodipine besylate/atorvastatin calcium were used in the study, and the majority of patients achieved their BP and LDL-C targets (varied between UK, Canada and Europe) with the 5/10 and 10/10 combination doses. [Figure 2](#fig2){ref-type="fig"} illustrates the percentages of patients attaining the BP and/or LDL-C goals.

In terms of safety profile, peripheral edema and myalgia occurred in a small proportion of patients, with myalgia occurring at a lower than expected rate.

GEMINI AALA
-----------

With a study design similar to that of GEMINI conducted in the United States, this trial included 1649 patients with diverse ethnic backgrounds across 27 countries in Asia, Africa, the Middle East and Latin America. Fifty-two percent of the patients in GEMINI AALA were of Asian and 15% of Hispanic ethnicity. Preliminary results show that an overall of 55.2% of patients achieved both JNC VI BP and NCEP ATP III LDL-C therapeutic goals after 14 weeks of treatment. A post-hoc analysis conducted among a subgroup of patients in Eastern Asian countries (excluding Australia, India, and Pakistan) further shows that the mean Framingham 10-year CHD risk score was reduced by 51.6% with Caduet single-pill treatment.

The treatment was generally well tolerated by patients. The majority of peripheral edema cases was mild to moderate in severity, and resulted in only 4 discontinuations. The incidence of myalgia was lower than expected, and none resulted in discontinuations.

CAPABLE
-------

The CAPABLE study conducted in the US, investigated the efficacy, safety and clinical utility of single-pill amlodipine/atorvastatin therapy among 499 African-American patients) with concomitant hypertension and dyslipidemia (under-researched group ([@b21]). Research to study therapies for the reduction of cardiovascular risk in the African-American population is particularly important as hypertension is more common among African-Americans than other US ethnic groups ([@b19]). The design of the CAPABLE study was similar to that of the GEMINI study, but enrolled 500 African-American men and women and analyzed BP and LDL-C goal attainment over 20 weeks rather than all ethnic groups with 14 weeks of follow up. Overall, at the end of CAPABLE 48.3% of patients reached both their blood pressure and LDL-C goals (compared with 0.8% at baseline) indicating the utility of amlodipine/atorvastatin to lower BP and lipid levels in this ethnic minority population, which is at a high risk of CVD events. A substudy of CAPABLE also demonstrated that amlodipine/atorvastatin improves 24 hour ambulatory BP ([@b22]).

Real-life prescribing data
--------------------------

The Caduet Concordance Research Program and Education (CARPE)-PBM Concordance Study ([@b44]) utilized claims data from a large US database, to assess differences in concordance between single-pill amlodipine/atorvastatin therapy in comparison with separate antihypertensive and lipid-lowering therapies. The study showed that the probability of achieving concordance with single-pill amlodipine/atorvastatin was almost twice that for amlodipine and atorvastatin taken separately. Compared with patients taking another antihypertensive and another statin separately, patients receiving amlodipine/atorvastatin were almost three times as likely to be adherent to both classes of medication ([@b44]).

Conclusion
==========

CVD is the most important cause of death and disability in the world. The most important treatable risk factors are hypertension and dyslipidemia. Despite effective therapies, patient concordance with multiple therapies is problematic. The amlodipine/atorvastatin single pill (Caduet) is the first combination therapy treating two risk factors simultaneously, targeting patients with co-existing hypertension and dyslipidemia. It has been shown to improve rates of goal attainment and to be as well tolerated as the parent compounds given individually.
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